Conditional survival after surgical treatment of melanoma: An analysis of the surveillance, epidemiology, and end results database

Annals of Surgical Oncology

Volumn 17, Issue 6, 2010, Pages 1662-1668

  Rueth, Natasha M ^a   Groth, Shawn S ^a   Tuttle, Todd M ^a   Virnig, Beth A ^b   Al Refaie, Waddah B ^a   Habermann, Elizabeth B ^a  

^a UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

^b UNIVERSITY OF MINNESOTA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; ARTICLE; CANCER INCIDENCE; CANCER LOCALIZATION; CANCER SURVIVAL; CLINICAL FEATURE; CONTROLLED STUDY; DATA BASE; FEMALE; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MALE; MELANOMA; PERIODIC MEDICAL EXAMINATION; SKIN SURGERY; ULCER;

ADULT; AGED; AGED, 80 AND OVER; COHORT STUDIES; FEMALE; HUMANS; MALE; MELANOMA; MIDDLE AGED; MINNESOTA; MULTIVARIATE ANALYSIS; POPULATION SURVEILLANCE; PROPORTIONAL HAZARDS MODELS; SEER PROGRAM; SKIN NEOPLASMS; SURVIVAL RATE; UNITED STATES;

EID: 77954814489     PISSN: 10689265     EISSN: 15344681     Source Type: Journal    
DOI: 10.1245/s10434-010-0965-8     Document Type: Article

References (26)

1. Cormier JN, Xing Y, Ding M, et al. Population-based assessment of surgical treatment trends for patients with melanoma in the era of sentinel lymph node biopsy. J Clin Oncol. 2005;23:6054-6062
2. National Comprehensive Cancer Network: Clinical Practice Guidelines in Oncology. http://www.nccn.org.
3. Erickson Foster J, Velasco JM, Hieken TJ. Adverse outcomes associated with noncompliance with melanoma treatment guidelines. Ann Surg Oncol. 2008;15:2395-2402
4. Gamel JW, George SL, Edwards MJ, Seigler HF. The long-term clinical course of patients with cutaneous melanoma. Cancer. 2002;95:1286-1293
5. Bilimoria KY, Balch CM, Bentrem DJ, et al. Complete lymph node dissection for sentinel node-positive melanoma: assessment of practice patterns in the United States. Ann Surg Oncol. 2008;15:1566-1576
6. Balch CM, Soong SJ, Atkins MB, et al. An evidence-based staging system for cutaneous melanoma. CA Cancer J Clin. 2004;54:131-149 (quiz 182-4).
7. Nowecki ZI, Rutkowski P, Michej W. The survival benefit to patients with positive sentinel node melanoma after completion lymph node dissection may be limited to the subgroup with a primary lesion Breslow thickness greater than 1.0 and less than or equal to 4 mm (pT2-pT3). Ann Surg Oncol. 2008;15:2223-2234
8. Choi M, Fuller CD, Thomas CR, Jr., Wang SJ. Conditional survival in ovarian cancer: results from the SEER dataset 1988- 2001. Gynecol Oncol. 2008;109:203-209
9. Huang L, Cronin KA, Johnson KA, Mariotto AB, Feuer EJ. Improved survival time: what can survival cure models tell us about population-based survival improvements in late-stage colorectal, ovarian, and testicular cancer? Cancer. 2008;112: 2289-2300
10. Janssen-Heijnen ML, Houterman S, Lemmens VE, et al. Prognosis for long-term survivors of cancer. Ann Oncol. 2007;18: 1408-1413
11. Kato I, Severson RK, Schwartz AG. Conditional median survival of patients with advanced carcinoma: surveillance, epidemiology, and end results data. Cancer. 2001;92:2211-2219
12. Skuladottir H, Olsen JH. Conditional survival of patients with the four major histologic subgroups of lung cancer in Denmark. J Clin Oncol. 2003;21:3035-3040
13. Wingo PA, Ries LA, Parker SL, Heath CW, Jr. Long-term cancer patient survival in the United States. Cancer Epidemiol Biomarkers Prev. 1998;7:271-282
14. National Cancer Institute: Surveillance, Epidemiology, and End Results (SEER) Program (www.seer.cancer.gov) SEER Database: Incidence-SEER Regs Public-Use November 2007.
15. Rouhani P, Hu S, Kirsner RS. Melanoma in Hispanic and black Americans. Cancer Control. 2008;15:248-253
16. Merrill RM, Henson DE, Barnes M. Conditional survival among patients with carcinoma of the lung. Chest. 1999;116:697-703.
17. American Joint Committee on Cancer: Cancer Staging Handbook from the AJCC Cancer Staging Manual (www.cancerstaging.org) Springer, 2002.
18. Balch CM, Soong S, Ross MI, et al. Long-term results of a multiinstitutional randomized trial comparing prognostic factors and surgical results for intermediate thickness melanomas (1.0 to 4.0 mm). Intergroup Melanoma Surgical Trial. Ann Surg Oncol. 2000;7:87-97.
19. Xing Y, Badgwell BD, Ross MI, et al. Lymph node ratio predicts disease-specific survival in melanoma patients. Cancer. 2009; 115:2505-2513
20. Haigh PI, DiFronzo LA, McCready DR. Optimal excision margins for primary cutaneous melanoma: a systematic review and meta-analysis. Can J Surg. 2003;46:419-426
21. Morton DL, Thompson JF, Cochran AJ, et al. Sentinel-node biopsy or nodal observation in melanoma. N Engl J Med. 2006;355:1307-1317
22. Slingluff CL, Jr., Dodge RK, Stanley WE, Seigler HF. The annual risk of melanoma progression. Implications for the concept of cure. Cancer. 1992;70:1917-1927
23. Karakousis GC, Gimotty PA, Czerniecki BJ, et al. Regional nodal metastatic disease is the strongest predictor of survival in patients with thin vertical growth phase melanomas: a case for SLN Staging biopsy in these patients. Ann Surg Oncol. 2007;14:1596-1603
24. Lasithiotakis K, Leiter U, Meier F, et al. Age and gender are significant independent predictors of survival in primary cutaneous melanoma. Cancer. 2008;112:1795-1804
25. McMasters KM, Noyes RD, Reintgen DS, et al. Lessons learned from the Sunbelt Melanoma Trial. J Surg Oncol. 2004;86:212-223
26. Chao C, Martin RC II, Ross MI, et al. Correlation between prognostic factors and increasing age in melanoma. Ann Surg Oncol. 2004;11:259-264